These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 31997802)

  • 21. Role of Neurotrophic Factors in Parkinson's Disease.
    Tome D; Fonseca CP; Campos FL; Baltazar G
    Curr Pharm Des; 2017; 23(5):809-838. PubMed ID: 27928963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo.
    Lindholm P; Voutilainen MH; Laurén J; Peränen J; Leppänen VM; Andressoo JO; Lindahl M; Janhunen S; Kalkkinen N; Timmusk T; Tuominen RK; Saarma M
    Nature; 2007 Jul; 448(7149):73-7. PubMed ID: 17611540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of GDF5 and GDNF as neuroprotective factors for postnatal dopamine neurons in ventral mesencephalic cultures.
    Jaumotte JD; Zigmond MJ
    J Neurosci Res; 2014 Nov; 92(11):1425-33. PubMed ID: 24916473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular mechanisms underlying the neuroprotection of environmental enrichment in Parkinson's disease.
    Alarcón TA; Presti-Silva SM; Simões APT; Ribeiro FM; Pires RGW
    Neural Regen Res; 2023 Jul; 18(7):1450-1456. PubMed ID: 36571341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AAV Vector-Mediated Gene Delivery to Substantia Nigra Dopamine Neurons: Implications for Gene Therapy and Disease Models.
    Albert K; Voutilainen MH; Domanskyi A; Airavaara M
    Genes (Basel); 2017 Feb; 8(2):. PubMed ID: 28208742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Other neurotrophic factors: glial cell line-derived neurotrophic factor (GDNF).
    Saarma M; Sariola H
    Microsc Res Tech; 1999 May 15-Jun 1; 45(4-5):292-302. PubMed ID: 10383122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies.
    Bartus RT; Kordower JH; Johnson EM; Brown L; Kruegel BR; Chu Y; Baumann TL; Lang AE; Olanow CW; Herzog CD
    Neurobiol Dis; 2015 Jun; 78():162-71. PubMed ID: 25841760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MANF protects dopamine neurons and locomotion defects from a human α-synuclein induced Parkinson's disease model in C. elegans by regulating ER stress and autophagy pathways.
    Zhang Z; Shen Y; Luo H; Zhang F; Peng D; Jing L; Wu Y; Xia X; Song Y; Li W; Jin L
    Exp Neurol; 2018 Oct; 308():59-71. PubMed ID: 29959908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glial cell line-derived neurotrophic factor improves intrastriatal graft survival of stored dopaminergic cells.
    Apostolides C; Sanford E; Hong M; Mendez I
    Neuroscience; 1998 Mar; 83(2):363-72. PubMed ID: 9460746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early Degeneration of Both Dopaminergic and Serotonergic Axons - A Common Mechanism in Parkinson's Disease.
    Grosch J; Winkler J; Kohl Z
    Front Cell Neurosci; 2016; 10():293. PubMed ID: 28066188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospects for the treatment of Parkinson's disease using neurotrophic factors.
    Hurelbrink CB; Barker RA
    Expert Opin Pharmacother; 2001 Oct; 2(10):1531-43. PubMed ID: 11825297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protocol for evaluation of neurotrophic strategies in Parkinson's disease-related dopaminergic and sympathetic neurons
    Hegarty SV; Sullivan AM; O'Keeffe GW
    J Biol Methods; 2016; 3(3):e50. PubMed ID: 31453215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson's disease and does not lead to a sustainable increase of brain-derived neurotrophic factor.
    Komnig D; Dagli TC; Habib P; Zeyen T; Schulz JB; Falkenburger BH
    J Neurochem; 2018 Dec; 147(5):678-691. PubMed ID: 30152864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease.
    Levivier M; Przedborski S; Bencsics C; Kang UJ
    J Neurosci; 1995 Dec; 15(12):7810-20. PubMed ID: 8613721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lentivirus-mediated Persephin over-expression in Parkinson's disease rats.
    Yin XF; Xu HM; Jiang YX; Zhi YL; Liu YX; Xiang HW; Liu K; Ding XD; Sun P
    Neural Regen Res; 2015 Nov; 10(11):1814-8. PubMed ID: 26807117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ret receptor tyrosine kinase immunoreactivity is altered in glial cell line-derived neurotrophic factor-responsive neurons following lesions of the nigrostriatal and septohippocampal pathways.
    Araujo DM; Hilt DC; Miller PJ; Wen D; Jiao S; Lapchak PA
    Neuroscience; 1997 Sep; 80(1):9-16. PubMed ID: 9252216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of mesenchymal stem cell on dopaminergic neurons, motor and memory functions in animal models of Parkinson's disease: a systematic review and meta-analysis.
    Park JM; Rahmati M; Lee SC; Shin JI; Kim YW
    Neural Regen Res; 2024 Jul; 19(7):1584-1592. PubMed ID: 38051903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exercise-Induced Neuroprotection and Recovery of Motor Function in Animal Models of Parkinson's Disease.
    Palasz E; Niewiadomski W; Gasiorowska A; Wysocka A; Stepniewska A; Niewiadomska G
    Front Neurol; 2019; 10():1143. PubMed ID: 31736859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.